Paradigm Capital Management Inc. NY Makes New Investment in Globus Medical, Inc. $GMED

Paradigm Capital Management Inc. NY purchased a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 886,499 shares of the medical device company’s stock, valued at approximately $70,042,000. Globus Medical accounts for approximately 1.9% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 13th largest position. Paradigm Capital Management Inc. NY owned 0.65% of Globus Medical as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Sanctuary Advisors LLC grew its holdings in Globus Medical by 2.3% during the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after purchasing an additional 151 shares in the last quarter. SBI Securities Co. Ltd. lifted its holdings in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Globus Medical by 1.6% during the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after purchasing an additional 199 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of GMED stock opened at $84.11 on Tuesday. The stock’s 50 day simple moving average is $80.71 and its 200 day simple moving average is $84.72. Globus Medical, Inc. has a twelve month low of $54.15 and a twelve month high of $101.40. The company has a market capitalization of $11.29 billion, a price-to-earnings ratio of 21.51, a PEG ratio of 1.40 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. Globus Medical’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the business posted $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts forecast that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Insider Activity

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 18.38% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on GMED. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Piper Sandler decreased their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. BMO Capital Markets began coverage on shares of Globus Medical in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price target on the stock. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus target price of $101.77.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.